Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting

Exelixis Inc (NASDAQ:EXEL) announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. 

• CONTACT-01 is a phase 3 trial evaluating Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) versus docetaxel in metastatic non-small cell lung cancer (NSCLC) without actionable mutations who experienced disease progression on or after treatment.
• Related: Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer.
• The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent.
• No new safety signals were identified. 
• Secondary endpoints included progression-free survival, objective response rate, and duration of response. 
• CONTACT-01 was sponsored by Roche Holdings AG (OTC:RHHBY) and co-funded by Exelixis. 
• Ipsen (OTC:IPSEY) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) opted to participate in the trial and are contributing to this study's funding under the companies' terms and respective collaboration agreements with Exelixis. 
• Price Action: EXEL shares are down 0.97% at $16.36 during the premarket session on the last check Friday.